Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD33xCD3 bispecific antibody
- Development stage
- Unknown
- Lead developer
- Y-mAbs Therapeutics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
CD33xCD3 bispecific antibody is a bispecific monoclonal antibody developed by Y-mAbs Therapeutics. It is designed to target CD33, a protein found on acute myeloid leukemia (AML) blasts, and CD3, a component of the T-cell receptor complex on T cells. By simultaneously binding to both targets, the antibody aims to bring T cells into close proximity with AML cells, thereby facilitating T-cell mediated killing of the cancerous cells. It is currently being investigated in pediatric patients with relapsed or refractory acute myeloid leukemia.
- Other names
- CD33xCD3CD-33xCD3CD 33xCD3
02
Targets
CD3 (T-cell surface glycoprotein CD3)CD33 (Myeloid cell surface antigen CD33)
Beyond the preview
Go deeper on CD33xCD3 bispecific antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD33xCD3 bispecific antibody.